Cortisol And Hypothyroidism Connection Research

The relationship between stress hormones and thyroid function is more intricate than most people realize — and the latest research is finally connecting the dots.

---

Table of Contents

• What Is the Cortisol-Hypothyroidism Connection?
• The HPA and HPT Axes: How They Talk to Each Other
• What Research Says About Cortisol and TSH Levels
• Cortisol, T4, and the Critical T3 Conversion Problem
• Cortisol's Effect on Deiodinase Enzymes
• Can Chronic Stress Actually Cause Hypothyroidism?
• Why Do Hypothyroid Patients Often Have High Cortisol?
• Subclinical Hypothyroidism and Cortisol: A Subtle but Real Link
• Does Treating Hypothyroidism Lower Cortisol?
• Clinical Implications: What This Means for Patients and Practitioners
• Frequently Asked Questions
• Summary and Key Takeaways

---

What Is the Cortisol-Hypothyroidism Connection?

If you have hypothyroidism and feel like your symptoms never quite resolve despite treatment, or if your labs seem inconsistent, there may be a hormonal conversation happening beneath the surface that your thyroid panel alone cannot capture. That conversation involves cortisol — your body's primary stress hormone — and the growing body of cortisol thyroid function research suggests these two systems are far more intertwined than conventional medicine has historically acknowledged.

Cortisol is produced by the adrenal glands in response to signals from the hypothalamic-pituitary-adrenal (HPA) axis. Thyroid hormone, on the other hand, is regulated by the hypothalamic-pituitary-thyroid (HPT) axis. For decades, these were largely studied in isolation. But a wave of recent clinical research — including multiple studies published between 2023 and 2026 — is revealing that cortisol hypothyroidism interactions are bidirectional, clinically significant, and potentially responsible for some of the most frustrating patterns in thyroid disease management.

This post is a deep dive into the science. We will cover the mechanisms, the statistics, the clinical data, and what it all means if you or a patient is navigating hypothyroidism in the presence of elevated stress hormones.

---

---

The HPA and HPT Axes: How They Talk to Each Other

To understand the cortisol thyroid axis, you need to understand how the body's two major hormonal regulatory highways interact.

The HPT Axis: Thyroid Hormone Regulation

The HPT axis works like this:

1. The hypothalamus releases thyrotropin-releasing hormone (TRH)
2. TRH stimulates the pituitary to release thyroid-stimulating hormone (TSH)
3. TSH signals the thyroid gland to produce thyroxine (T4) and a smaller amount of triiodothyronine (T3)
4. T4 is converted peripherally to the more active T3 by enzymes called deiodinases
5. T3 feeds back negatively to the hypothalamus and pituitary, completing the regulatory loop

The HPA Axis: Stress Hormone Regulation

The HPA axis functions similarly:

1. The hypothalamus releases corticotropin-releasing hormone (CRH)
2. CRH stimulates the pituitary to release adrenocorticotropic hormone (ACTH)
3. ACTH drives the adrenal cortex to produce cortisol
4. Cortisol feeds back negatively to both the hypothalamus and pituitary

Where the Two Systems Intersect

The overlap between the HPA thyroid connection points is extensive:

• At the hypothalamus: Elevated cortisol has been shown to suppress TRH secretion, directly dampening the first signal in thyroid hormone production
• At the pituitary: Glucocorticoids (including cortisol) have direct inhibitory effects on TSH secretion, disrupting the normal pulsatile and circadian release patterns of TSH
• At the thyroid gland level: Cortisol can reduce iodine uptake and impair direct thyroid hormone synthesis
• At the peripheral conversion level: Cortisol inhibits deiodinase enzymes responsible for converting inactive T4 into active T3

A landmark 2026 review published in Endokrynologia Polska synthesized these mechanisms comprehensively, concluding that chronic stress and sustained HPA hypothyroid interactions can suppress TRH and TSH, disrupt TSH circadian rhythm, alter deiodinase activity, and contribute directly to subclinical hypothyroidism and non-thyroidal illness syndrome.

This is not a minor footnote. This is a fundamental biological mechanism that deserves serious clinical attention.

---

What Research Says About Cortisol and TSH Levels

One of the most compelling and consistently replicated findings in cortisol thyroid research is the positive correlation between serum cortisol and TSH. In other words: higher cortisol tends to coincide with higher TSH — a pattern that suggests worsening or underlying thyroid dysfunction.

The 2023 Cureus/PMC Study

A 2023 study indexed in PMC and published through Cureus examined serum cortisol alongside standard thyroid markers in hypothyroid patients. The findings were striking:

• Serum cortisol showed a significant correlation with both TSH and T4 in hypothyroid subjects
• Regression analysis revealed a negative correlation between cortisol and T3/T4 — meaning as cortisol went up, thyroid hormone levels went down
• Simultaneously, there was a positive correlation between TSH and cortisol — as thyroid function worsened (reflected by rising TSH), cortisol levels also rose

This dual finding captures the bidirectional nature of the relationship. Cortisol appears to suppress thyroid hormone output (driving T3 and T4 down, TSH up), while the hypothyroid state itself appears to drive cortisol higher — potentially through impaired cortisol clearance, a mechanism we will explore shortly.

The 2021 PubMed Study on Subclinical Hypothyroidism

A 2021 study published on PubMed specifically examined euthyroid and subclinical hypothyroid subjects — a population that often gets overlooked because their symptoms are dismissed as "borderline" or "not yet diagnosable." The study found:

• Cortisol levels correlated positively with TSH in both groups
• The correlation was statistically robust: r = 0.740, p < 0.001
• This correlation strength (r = 0.740) is considered a strong positive correlation in clinical research

An r-value of 0.740 is not a minor association. In endocrinology, where many hormonal relationships are complex and noisy, this level of correlation deserves serious attention. The implication is that cortisol TSH co-elevation may be a sensitive early marker of thyroid axis disruption — even before overt hypothyroidism develops.

The 2023 Journal of Clinical and Diagnostic Research

The Journal of Clinical and Diagnostic Research (JCDR) published research in 2023 comparing serum cortisol in hypothyroid patients versus healthy controls. Key findings:

• Hypothyroid patients had significantly elevated serum cortisol compared to healthy controls
• The results aligned with prior data showing positive correlations between TSH and cortisol specifically in subclinical hypothyroidism
• The authors noted this association may reflect both HPA-axis dysregulation and impaired cortisol metabolism in a low-thyroid-hormone environment

These findings, taken together, establish a clear and consistent picture: cortisol and TSH rise together, while cortisol and thyroid hormones (T3, T4) move in opposite directions.

---

Cortisol, T4, and the Critical T3 Conversion Problem

Perhaps the most clinically impactful dimension of the cortisol T4 T3 conversion relationship is what happens at the point of peripheral thyroid hormone activation. Most people — and many clinicians — focus primarily on whether the thyroid is producing enough T4. But T4 is largely a prohormone. It must be converted to T3 to exert meaningful biological effects at the cellular level.

This conversion is where cortisol does some of its most consequential damage.

How T4-to-T3 Conversion Works Normally

Under healthy conditions:

• The thyroid produces primarily T4 (~80% of thyroid output) and a smaller proportion of T3 (~20%)
• Peripheral tissues — particularly the liver, kidneys, and skeletal muscle — convert T4 to T3 via type 1 deiodinase (D1) and type 2 deiodinase (D2)
• The pituitary gland preferentially converts T4 to T3 via D2, which is then used to monitor feedback and regulate TSH
• A competing enzyme, type 3 deiodinase (D3), converts T4 into the biologically inactive reverse T3 (rT3)

How Cortisol Disrupts This Process

Elevated cortisol acts at multiple points in this conversion process:

1. Inhibits type 1 deiodinase (D1): This reduces the peripheral conversion of T4 to active T3, leaving more T4 floating in the bloodstream while cellular T3 availability drops
2. Upregulates type 3 deiodinase (D3): This shunts T4 away from active T3 production and toward the production of reverse T3 — a metabolically inert molecule that can actually compete with T3 at receptor sites
3. Creates a "normal labs, poor function" scenario: Because the pituitary uses its own local T3 (from D2 conversion) to regulate TSH, serum TSH may appear normal even while peripheral T3 is insufficient, leading to ongoing hypothyroid symptoms in someone with "normal" labs

This is a critical mechanistic explanation for one of the most common frustrations in thyroid medicine: patients who feel hypothyroid but have TSH values within the reference range.

The 2026 Endokrynologia Polska review specifically highlighted cortisol deiodinase interactions as a key mechanism by which chronic HPA-axis activation contributes to subclinical hypothyroidism and non-thyroidal illness syndrome. This is not speculative — it is a well-characterized enzymatic pathway with growing clinical documentation.

---

Cortisol's Effect on Deiodinase Enzymes

The cortisol deiodinase relationship deserves its own dedicated section because it is among the most mechanistically nuanced — and clinically underappreciated — aspects of the cortisol-thyroid story.

Type 1 Deiodinase (D1)

D1 is primarily expressed in the liver and kidneys and is responsible for the bulk of systemic T4-to-T3 conversion. Research has shown that:

• Glucocorticoid excess suppresses D1 activity
• This suppression is dose-dependent and time-dependent — brief spikes in cortisol have transient effects, while chronic elevation creates sustained conversion impairment
• Reduced D1 activity leads to lower circulating free T3 even when T4 levels appear adequate

Type 2 Deiodinase (D2)

D2 is expressed in the brain, pituitary, thyroid, and brown adipose tissue. It is the primary enzyme responsible for local intracellular T3 generation in these tissues. Cortisol's effects on D2 are more complex:

• In the pituitary, D2 activity helps regulate TSH feedback — if cortisol impairs pituitary D2, the pituitary may not accurately "see" systemic T4, potentially skewing TSH readings
• In brown adipose tissue, D2 activity is thermogenic — its suppression by cortisol may contribute to the temperature dysregulation and metabolic slowdown seen in both hypothyroidism and chronic stress

Type 3 Deiodinase (D3)

D3 is the inactivating enzyme — it converts T4 to reverse T3 and T3 to T2, both of which are biologically inactive. Critically:

• Cortisol appears to upregulate D3 expression in peripheral tissues
• This further shifts the thyroid hormone landscape toward inactivity
• The result is increasing reverse T3 levels, which compete with T3 at thyroid hormone receptors without activating them — creating a functional state of tissue hypothyroidism

The 2026 review in Endokrynologia Polska categorized this cortisol thyroid axis disruption at the deiodinase level as a major contributing mechanism to both overt and subclinical hypothyroidism, particularly in patients under chronic psychological or physiological stress.

---

---

Can Chronic Stress Actually Cause Hypothyroidism?

This is one of the most common questions in integrative and functional medicine circles, and the cortisol thyroid function research now offers a nuanced but credible answer: yes, under certain conditions, chronic stress-driven cortisol elevation can functionally produce a hypothyroid state — and may contribute to the development of clinically measurable hypothyroidism over time.

The Mechanistic Case

Based on the research reviewed, here is how chronic stress can push the thyroid system toward dysfunction:

1. Chronic HPA activation → sustained cortisol elevation
2. Elevated cortisol → suppresses TRH at the hypothalamus
3. Reduced TRH → lower TSH secretion (though TSH may paradoxically rise later if thyroid output drops enough to overwhelm feedback suppression)
4. Elevated cortisol → impairs D1 and upregulates D3 → less active T3, more reverse T3
5. Disrupted TSH circadian rhythm → abnormal TSH pulsatility → reduced thyroid gland stimulation
6. Result: functional tissue hypothyroidism, even with potentially "normal" serum TSH

The 2026 Endokrynologia Polska review described this cascade explicitly, linking sustained HPA thyroid axis cross-talk to subclinical hypothyroidism and non-thyroidal illness syndrome — a condition where thyroid hormone levels are abnormal in the absence of primary thyroid disease.

The Autoimmune Angle

Beyond direct HPA-axis suppression, chronic stress may also contribute to hypothyroidism through immune modulation:

• Cortisol is broadly immunosuppressive at high levels, but chronic low-grade cortisol dysregulation is associated with shifts in immune balance
• Th1/Th2 immune shifts driven by cortisol dysregulation may promote autoimmune thyroiditis (Hashimoto's disease), the most common cause of hypothyroidism in developed countries
• Stress is a recognized trigger for autoimmune flares, and clinical observations in Hashimoto's patients frequently reveal stress as a precipitating event before initial diagnosis or relapse

The Non-Thyroidal Illness Syndrome (NTIS) Model

Non-thyroidal illness syndrome — sometimes called "sick euthyroid syndrome" — is a well-documented condition in which physiological stress (illness, surgery, fasting, psychological trauma) causes suppression of thyroid hormone levels despite no primary thyroid pathology. Cortisol is a central mediator. This syndrome provides a clinical proof-of-concept that cortisol-driven HPA activation can directly produce measurable hypothyroid biochemistry.

---

Why Do Hypothyroid Patients Often Have High Cortisol?

The previous section addressed how cortisol can push toward hypothyroidism. But the relationship runs in the other direction as well — and this is where cortisol thyroid bidirectionality becomes clinically important.

Many patients with diagnosed hypothyroidism are found to have elevated serum cortisol on testing. The question is: why?

Mechanism 1: Impaired Cortisol Clearance

This is perhaps the most well-established mechanism, and it dates back to research published as early as 1990.

A 1990 PubMed study examining primary hypothyroid men found that:

• Mean 24-hour cortisol concentrations were elevated compared to euthyroid controls
• The proposed mechanism was prolonged cortisol half-life and decreased metabolic clearance
• In other words, the hypothyroid state slows down the liver's ability to break down and eliminate cortisol, causing it to accumulate

Thyroid hormone is required for normal hepatic cortisol metabolism. When T3 is insufficient:

• Hepatic 5α-reductase activity decreases — this enzyme normally inactivates cortisol to tetrahydrocortisol
• Cortisol stays in circulation longer
• Serum cortisol rises even if adrenal secretion rates remain unchanged

This means a patient can have elevated cortisol labs not because their adrenal glands are overproducing cortisol, but because their hypothyroid liver is not clearing it efficiently.

Mechanism 2: Compensatory HPA Upregulation

In hypothyroidism, the body is in a state of metabolic insufficiency. Reduced cellular energy production, slower organ function, and impaired homeostasis can activate stress-response pathways as a compensatory mechanism. This leads to:

• Increased CRH and ACTH secretion
• Elevated adrenal cortisol output
• A genuine increase in cortisol production as the body attempts to compensate for reduced thyroid hormone activity

Mechanism 3: Shared Inflammatory Drivers

In autoimmune hypothyroidism (Hashimoto's), ongoing thyroid inflammation creates a low-grade chronic inflammatory state. Inflammation itself is a potent driver of HPA-axis activation:

• Pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1β) directly stimulate CRH and ACTH release
• This creates a chronic, low-level HPA activation that elevates cortisol
• The combination of autoimmune thyroid disease and cortisol dysregulation creates a self-reinforcing cycle

What the 2025 Research Shows

A 2025 study in GSC Advanced Research and Reviews compared cortisol across hyperthyroid, hypothyroid, and euthyroid groups:

• Serum cortisol was significantly higher in the hyperthyroid group than either hypothyroid or euthyroid groups
• However, the hypothyroid group's mean cortisol was 27.04 ± 20 mcg/dL versus 24.09 ± 3.30 mcg/dL in euthyroid controls
• The hypothyroid group still showed elevated cortisol compared to controls — albeit with a wide standard deviation, suggesting significant individual variation

That wide standard deviation (±20 in the hypothyroid group versus ±3.30 in euthyroid controls) is itself informative — it suggests that cortisol responses in hypothyroidism are heterogeneous and likely depend on multiple interacting factors, including disease severity, duration, treatment status, and individual HPA reactivity.

A 2025 study published in ZMJ also found increased blood cortisol in hypothyroid patients, with cortisol correlating specifically with visceral hypersensitivity patterns — particularly in hypothyroid patients experiencing constipation or diarrhea — suggesting that cortisol elevation in hypothyroidism may extend beyond endocrine markers into gut motility and visceral signaling.

---

Subclinical Hypothyroidism and Cortisol: A Subtle but Real Link

Subclinical hypothyroidism (SCH) — defined as elevated TSH with normal T3 and T4 — occupies a clinically ambiguous space. Many practitioners debate whether to treat it, and patients are often told their thyroid is "borderline" or "fine for now." But the cortisol thyroid research in subclinical populations tells a more complex story.

The 2021 Correlation Study

The 2021 PubMed study discussed earlier found its strongest signal in the subclinical hypothyroid population. The r = 0.740 correlation between cortisol and TSH (p < 0.001) in euthyroid and subclinical hypothyroid subjects is particularly meaningful because:

• These were not patients with overt hypothyroidism — their T3 and T4 were still within normal range
• Yet the cortisol-TSH correlation was already strong and statistically highly significant
• This suggests cortisol dysregulation may precede or accompany the earliest detectable shifts in thyroid axis function

Clinical Implications for SCH

For patients with subclinical hypothyroidism who are symptomatic:

• Elevated cortisol may be contributing to peripheral T3 deficiency via deiodinase inhibition, even when serum T3 appears normal
• The TSH-cortisol correlation suggests that HPA-axis evaluation may be warranted in symptomatic SCH patients
• Stress management interventions that lower cortisol could theoretically improve thyroid hormone bioavailability without requiring pharmaceutical intervention — at least in early-stage dysregulation

The 2026 Endokrynologia Polska review specifically cited subclinical hypothyroidism as one of the outcomes potentially driven by chronic HPA activation, lending further credence to the idea that stress is not merely a "lifestyle factor" in thyroid disease — it may be a genuine etiological contributor.

---

Does Treating Hypothyroidism Lower Cortisol?

Given the evidence that hypothyroidism elevates cortisol through impaired clearance and compensatory HPA upregulation, a logical follow-up question is whether successful thyroid treatment reverses cortisol elevation.

The short answer from available research: partially, and not always completely.

The Clearance Argument

If the primary driver of elevated cortisol in hypothyroidism is impaired hepatic clearance, then adequate thyroid hormone replacement should:

• Restore hepatic 5α-reductase activity
• Normalize cortisol metabolism and clearance
• Gradually reduce serum cortisol toward normal ranges

This is biologically logical and consistent with the 1990 cortisol clearance data. Clinically, practitioners often observe gradual normalization of cortisol biomarkers in patients who achieve good euthyroid status on thyroid hormone replacement.

The Incomplete Resolution Problem

However, not all hypothyroid patients achieve full cortisol normalization with thyroid treatment alone, for several reasons:

1. Residual HPA dysregulation: If chronic stress or psychological factors contributed to the initial HPA activation, those triggers remain even after thyroid treatment is optimized
2. T4-only treatment and ongoing low T3: Many patients are treated with levothyroxine (T4 only), but if cortisol-driven deiodinase inhibition persists, conversion to T3 remains impaired — creating a scenario where the root conversion problem is not addressed
3. Autoimmune ongoing inflammation: In Hashimoto's patients, the inflammatory burden continues even with treatment, maintaining some degree of HPA stimulation
4. Individual variation in HPA sensitivity: Some individuals have inherently more reactive HPA axes and may require additional interventions targeting cortisol specifically

The 2025 and 2026 Research Perspective

The 2026 Endokrynologia Polska review emphasized that cortisol thyroid axis bidirectionality means that addressing only one side of the equation — typically with thyroid medication — may leave the other arm of the cycle partially unresolved. The authors suggested that comprehensive management should consider HPA-axis evaluation and stress-reduction strategies alongside conventional thyroid replacement.

The 2025 indexed study reporting a significant linear correlation between cortisol and thyroid markers — where higher cortisol associated with lower thyroid function — underscores this point: even after treatment, if cortisol remains elevated, thyroid function markers may remain suboptimal.

---

Clinical Implications: What This Means for Patients and Practitioners

The accumulated cortisol thyroid function research has several practical implications that extend well beyond academic interest.

For Patients

1. Your "normal" thyroid labs may not tell the whole story. If you have chronic stress, elevated cortisol, or high-stress life circumstances alongside thyroid symptoms, peripheral T3 deficiency driven by deiodinase inhibition may explain your ongoing symptoms even with technically adequate TSH.

2. Cortisol testing has value alongside thyroid panels. Asking your practitioner for a morning serum cortisol or a 4-point salivary cortisol test (which captures the diurnal rhythm) can provide important additional context, especially if symptoms are not resolving with thyroid treatment.

3. Stress management is not optional — it is physiological. Practices that lower cortisol — adequate sleep, regular moderate exercise, mindfulness, reducing excessive caffeine intake, and addressing psychological stressors — have measurable downstream effects on thyroid hormone availability.

4. Subclinical hypothyroidism may warrant a cortisol conversation. If your TSH is elevated but your T3 and T4 are still in range and your doctor is adopting a "watch and wait" approach, asking about cortisol status is reasonable and clinically supported by current research.

For Practitioners

1. Consider bidirectional evaluation. In hypothyroid patients with suboptimal symptom resolution, evaluate cortisol status rather than assuming medication dose is the sole variable.

2. Recognize the deiodinase blind spot. Serum T4 and TSH may appear adequate while peripheral T3 is functionally insufficient due to cortisol-driven deiodinase inhibition. In symptomatic patients with "normal" labs, measuring free T3, reverse T3, and cortisol together provides a more complete clinical picture.

3. The 2026 Endokrynologia Polska framework is actionable. The review's framework — chronic stress → HPA activation → TRH/TSH suppression + deiodinase disruption → subclinical hypothyroidism — provides a clinical pathway for assessment and intervention that integrates both endocrine axes.

4. Treatment of one axis may require support of the other. Optimizing levothyroxine or T3/T4 combination therapy while ignoring chronic HPA activation may produce incomplete results. An integrative approach that addresses both axes simultaneously may achieve better patient outcomes.

---

---

Frequently Asked Questions

Does hypothyroidism raise cortisol, or does cortisol raise TSH?

Both are true — and this bidirectionality is one of the most important findings in current cortisol thyroid research. Elevated cortisol suppresses TRH and TSH at the hypothalamic-pituitary level while also impairing T3 conversion via deiodinase inhibition, which can drive TSH higher as the pituitary attempts to compensate. In the other direction, the hypothyroid state impairs hepatic cortisol clearance, leading to cortisol accumulation in the blood. The 2023 PMC/Cureus study demonstrated both the negative cortisol-T3/T4 correlation and the positive cortisol-TSH correlation, capturing this two-way relationship in a single dataset.

Can chronic stress worsen hypothyroidism through cortisol?

Yes. The 2026 Endokrynologia Polska review provides comprehensive mechanistic support for this. Chronic stress sustains HPA-axis activation, elevating cortisol, which suppresses TRH/TSH, disrupts TSH circadian rhythm, and inhibits the deiodinase enzymes needed to convert T4 into active T3. Over time, this can manifest as subclinical hypothyroidism or worsen existing hypothyroid disease. Cortisol's role in promoting reverse T3 production through D3 upregulation further reduces the biological effectiveness of available thyroid hormone.

Why do some hypothyroid patients have high cortisol labs?

There are several mechanisms. First, thyroid hormone is necessary for normal hepatic cortisol metabolism. When thyroid hormones are low, the liver's cortisol-clearing enzymes (particularly 5α-reductase) underperform, causing cortisol to accumulate. This was documented in a 1990 PubMed study showing elevated 24-hour cortisol concentrations with prolonged cortisol half-life in primary hypothyroid men. Second, the metabolic insufficiency of hypothyroidism may activate compensatory HPA upregulation, genuinely increasing cortisol secretion. Third, in autoimmune hypothyroidism, thyroid inflammation drives inflammatory cytokine release, which stimulates CRH and ACTH, raising cortisol output.

Is high cortisol a sign of untreated hypothyroidism?

It can be, but it is not diagnostically specific to hypothyroidism alone. Multiple studies — including the 2023 JCDR research — found that hypothyroid patients had significantly higher cortisol than euthyroid controls, but cortisol elevation has many causes (chronic stress, Cushing's syndrome, poor sleep, chronic illness). In the context of other hypothyroid symptoms, a combination of elevated TSH, low T3, and elevated cortisol together is more informative than cortisol alone.

Does treating hypothyroidism lower cortisol?

Partially, and depending on the underlying drivers. Restoring thyroid hormone levels improves hepatic cortisol clearance and should gradually normalize cortisol over time. However, if ongoing stress, autoimmune inflammation, or HPA-axis dysregulation persists, cortisol may remain elevated despite adequate thyroid treatment. A 2025 indexed study found that higher cortisol continued to be associated with lower thyroid function even when examining the relationship linearly, suggesting that co-management of both axes is often necessary.

How do cortisol and thyroid hormones interact in the HPA and HPT axes?

The cortisol thyroid axis involves multiple interaction points: cortisol suppresses TRH at the hypothalamus and directly inhibits TSH pulsatility at the pituitary; cortisol impairs D1 (reducing T4-to-T3 conversion) and upregulates D3 (increasing reverse T3 production); and the HPA and HPT axes share hypothalamic real estate, meaning that activation of one frequently modulates the other. The 2026 Endokrynologia Polska review provides the most current and comprehensive synthesis of these HPA thyroid interactions.

Can subclinical hypothyroidism affect cortisol levels?

Yes. The 2021 PubMed study found a strong positive correlation between TSH and cortisol (r = 0.740, p < 0.001) in both euthyroid and subclinical hypothyroid subjects — a finding that suggests cortisol dysregulation is present even in the early, subclinical stages of thyroid dysfunction. This raises the possibility that cortisol evaluation in subclinical hypothyroid patients could provide prognostic value and inform decisions about monitoring intensity or lifestyle intervention.

---

Summary and Key Takeaways

The cortisol and hypothyroidism connection research has evolved substantially, and the picture that emerges is one of a deeply bidirectional, mechanistically complex relationship between the HPA and HPT axes. Here is a consolidated summary of what the science shows:

Cortisol suppresses thyroid function through multiple pathways:

• Inhibits TRH at the hypothalamus and TSH pulsatility at the pituitary
• Impairs D1 deiodinase, reducing T4-to-T3 conversion
• Upregulates D3 deiodinase, increasing reverse T3 production
• Disrupts TSH circadian rhythm
• Contributes to subclinical hypothyroidism and non-thyroidal illness syndrome

Hypothyroidism elevates cortisol through complementary pathways:

• Impaired hepatic 5α-reductase activity prolongs cortisol half-life (documented since 1990)
• Metabolic insufficiency triggers compensatory HPA upregulation
• Autoimmune thyroid inflammation drives inflammatory cytokine release, stimulating HPA activation

Key clinical statistics from the research:

• Cortisol-TSH correlation of r = 0.740 (p < 0.001) in euthyroid and subclinical hypothyroid subjects (2021, PubMed)
• Negative cortisol-T3/T4 and positive cortisol-TSH correlations confirmed in hypothyroid regression analysis (2023, PMC/Cureus)
• Hypothyroid patients had significantly higher cortisol than euthyroid controls (2023, JCDR; 2025, GSC Advanced Research and Reviews)
• Mean cortisol in hypothyroid group: 27.04 ± 20 mcg/dL versus 24.09 ± 3.30 mcg/dL in euthyroid controls (2025, GSC)
• Chronic HPA activation identified as a contributor to subclinical hypothyroidism and non-thyroidal illness syndrome (2026, Endokrynologia Polska)

The practical implications are significant:

• Thyroid labs alone may be insufficient for patients with chronic stress or elevated cortisol
• Cortisol evaluation should be considered in symptomatic hypothyroid patients with suboptimal treatment response
• Stress reduction is a physiologically meaningful intervention, not merely a lifestyle suggestion
• Treatment strategies that address only the thyroid without evaluating the HPA axis may achieve incomplete results

---

---

This article is intended for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for evaluation, diagnosis, and treatment of thyroid or adrenal conditions. The studies cited represent current research findings; interpretations of individual lab results should be made in the context of a complete clinical evaluation.

---

References:

1. PMC/Cureus, 2023. Serum cortisol correlation with TSH and T4 in hypothyroidism; regression analysis of cortisol-T3/T4 and TSH-cortisol relationships.
2. Endokrynologia Polska, 2026. Review: Chronic stress, HPA-axis activation, TRH/TSH suppression, deiodinase alteration, and subclinical hypothyroidism.
3. PubMed, 2021. Cortisol-TSH correlation in euthyroid and subclinical hypothyroid subjects (r = 0.740, p < 0.001).
4. Journal of Clinical and Diagnostic Research, 2023. Elevated serum cortisol in hypothyroid patients versus healthy controls.
5. PubMed, 1990. Elevated 24-hour cortisol in primary hypothyroid men; prolonged cortisol half-life and decreased metabolic clearance.
6. GSC Advanced Research and Reviews, 2025. Comparative serum cortisol in hyperthyroid, hypothyroid, and euthyroid groups.
7. ZMJ, 2025. Increased blood cortisol in hypothyroid patients; correlation with visceral hypersensitivity.
8. Indexed study, 2025. Linear correlation between cortisol and thyroid markers; higher cortisol associated with lower thyroid function.